Corbus Pharmaceuticals will host an in-person and virtual event at ASCO 2026 to present updated Phase 1/2 data on CRB-701, a next-gen antibody-drug conjugate for head and neck squamous cell carcinoma (HNSCC). The data includes clinical response durability and patient subgroup analysis from 75 participants. The event features leading oncology experts and follows recent FDA alignment on CRB-701's regulatory path. This presentation highlights Corbus's progress in developing innovative cancer therapies targeting Nectin-4 expressing tumors.
Riskified Ltd. posted strong Q2 2026 results with revenue rising 22% year-over-year to $98.69 million, its best growth in over four years, driven by rising demand for its e-commerce fraud prevention services. However, earnings per share came in at $0...
Outlook Therapeutics has seen its analyst consensus price target increase from $1.90 to $2.80, driven by promising Phase III trial results for its eye disease drug ONS-5010 and strategic partnerships. The company is expected to beat upcoming quarterl...
Ball Corporation's stock has gained 3.14% over the past month but recently dropped 4.52%, presenting a potential buying opportunity. Analysts forecast a 20.27% growth potential with a target price of $75, reflecting confidence in the company's future...
Kyndryl Holdings, an IT infrastructure services provider spun off from IBM, has seen its stock rise nearly 12% over the past 30 days but recently dipped 3.77% in the last 10 days, possibly creating a buying opportunity. Analysts forecast a 12.85% ups...
The Honest Company reported Q2 earnings of $0.04 per share, doubling expectations, despite a 10.9% revenue drop due to strategic business exits. Organic revenue grew 6.7%, showing strength in core products, while profitability improved with a gross m...
